Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|June 16, 2018
Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 InhibitorsMaiko Nomoto, Jim Ferry, Ziad Hussein
British Journal of Clinical Pharmacology|April 3, 2016
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trialsOneeb Majid, Antonio Laurenza, Jim Ferry, et al.
Acta Neurologica Scandinavica|May 21, 2020
Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuationEdgar Schuck, Jim Ferry, Barry Gidal, et al.
Epilepsia|June 19, 2013
Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizuresBarry E Gidal, Jim Ferry, Oneeb Majid, et al.
Epilepsy Research|December 24, 2018
Potential protein-binding displacement interactions with perampanel: An in vitro analysisBarry E Gidal, Jim Ferry, Antonio Laurenza, et al.
Epilepsy Research|May 20, 2015
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studiesAntonio Laurenza, Haichen Yang, Betsy Williams, et al.
Epilepsy & Behavior : E&B|May 10, 2021
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for cliniciansBarry E Gidal, Jim Ferry, Larisa Reyderman, et al.
Epilepsy Research|June 20, 2015
Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trialsHaichen Yang, Antonio Laurenza, Betsy Williams, et al.
Clinical Pharmacology in Drug Development|March 25, 2017
Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White SubjectsMaiko Nomoto, Gina Pastino, Bhaskar Rege, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2018
Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancerSeiichi Hayato, Robert Shumaker, Jim Ferry, et al.
Pageof 3